Optimal treatment for chronic active Epstein–Barr virus disease

Cohen, Jeffrey I.

doi:10.1111/j.1399-3046.2008.01095.x

Cited by 51 publications

(48 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Allogeneic SCT has been considered as a consolidation treatment for ENKTL and ANKL because donor-derived T cells might effectively eradicate the EBV-infected tumor cells. Indeed, allogeneic SCT produced successful outcomes in patients with chronic active EBV infection, which is closely related to the occurrence of ENKTL and ANKL [27]. However, no randomized, prospective study has evaluated the role of allogeneic SCT in ENKTL and ANKL because they are very rare disorders, with a higher geographic prevalence in East Asia [28].…”

Section: Discussionmentioning

confidence: 99%

Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation

Jeong

Song

Park

et al. 2018

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Natural killer (NK)/T cell lymphoid malignancy comprises extranodal NK/T cell lymphoma (ENKTL) and aggressive NK cell leukemia (ANKL), and the outcomes for advanced or relapsed/refractory ENKTL and ANKL remain poor. Allogeneic stem cell transplantation (SCT) can be used as a frontline consolidation treatment to prevent the relapse of advanced disease or as salvage treatment after chemotherapy for relapsed sensitive disease. We retrospectively analyzed 36 patients (ENKTL, n = 26; ANKL, n = 10) who underwent upfront (n = 19) and salvage allogeneic SCT (n = 17) at 6 hospitals. Patients received myeloablative (n = 25) or reduced-intensity (n =11) conditioning regimens depending on the institute's policy. The median age at the time of allogeneic SCT was 37 years (range, 17 to 62), and more patients with ANKL (8/10) received upfront allogeneic SCT than ENKTL patients (11/26). Disease status before allogeneic SCT, conditioning regimen, and donor source did not differ between upfront and salvage allogeneic SCT groups. Febrile neutropenia (n = 20) and acute graft-versus-host disease (n = 16) were common adverse events. The median overall survival (OS) and progression-free survival (PFS) after allogeneic SCT were 11.8 months and 10.0 months, respectively. Twelve patients died from disease relapse and 12 from nondisease-related causes. Ten deaths occurred within 100 days after allogeneic SCT (10/24); these were mostly related to disease relapse (n = 8). The OS after allogeneic SCT did not differ between ENKTL and ANKL (P = .550) or between upfront and salvage SCT (P = .862). Complete chimerism was significantly associated with better PFS (P < .001). No significant differences in PFS were observed based on the conditioning regimen or source of stem cells (P > .05). Allogeneic SCT may be beneficial for patients with ENKTL and ANKL given that some patients were able to maintain their remission after allogeneic SCT. However, allogeneic SCT should only be performed in highly selected patients because the risks of disease relapse and nondisease-related mortality remain high.

show abstract

Section: Discussionmentioning

confidence: 99%

Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation

Jeong

Song

Park

et al. 2018

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

“…EBV is a human herpes virus (HHV‐4) and is exclusively seen in humans with a quoted incidence of up to 95% . Historically, it was the first virus implicated in tumorigenesis.…”

Section: Oncoviridaementioning

confidence: 99%

“…Infection in adolescent and young adult populations manifests itself as infectious mononucleosis . Following acute infection, which is limited by cytotoxic T cells, the virus enters B cells (see Figure ), transforming them into active lymphoblasts .…”

Section: Oncoviridaementioning

confidence: 99%

Importance of the immune system in head and neck cancer

et al. 2019

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) are a heterogeneous group of tumors, mainly caused by exposure to cigarette smoke and/or alcohol. In recent years, a virally driven subset of cancers driven by human papillomavirus subtype 16 [HPV‐16]) has emerged. Our own data and data from other groups have demonstrated the favorable clinical outcome of HPV‐driven oropharyngeal tumors and in both HPV+ and HPV− cancers the importance of a high density of tumor‐associated lymphocytes for survival. These data underpin manipulation and activation of the patients' immune system by treatment, and as a result immunotherapy is rapidly taking its place in the management of HNSCC. Here we review the role the immune system in relation to HNSCC and consider the implications these have for HNSCC immunotherapy. Studies to quantify survival benefits and treatment‐associated toxicities are ongoing.

show abstract

“…Термин ХАЭБВИ первоначально использовался для описания пациентов с симптомами хронического или рецидивирующего инфекционного мононуклеоза, а теперь он определяет ВЭБ-ассоциированные заболевания продолжительностью более 3 месяцев, ВЭБ-позитивные лимфопролиферативные заболевания с повышенным уровнем вируса в пораженных тканях, высоким уровнем вирусемии или увеличением титра анти-EBV IgG, при отсутствии первичных или вторичных проявлений [43,44,45,46,47].…”

Section: клиническая картинаunclassified

“…ХЭБВИ наиболее часто описывается в Восточной Азии, где пролиферирующими клетками обычно являются T-или NK-клетки [45]. Клинически он протекает агрессивно, с осложнениями от прогрессирования ГЛГ и/или лимфомы, диссеминированной внутрисосудистой коагулопатией, аневризмами коронарных артерий, поражением центральной нервной системы (ЦНС), миокардитом, пневмонитом и перфорацией желудочнокишечного тракта [44,45].…”

Section: клиническая картинаunclassified

The clinical and immunological features of Epstein-Barr virus infection

Понежева¹,

Гришаева²,

Плоскирева³

2019

Immunopathol Allergol Infectol

View full text Add to dashboard Cite

Приведен обзор современных представлений о структуре Эпштейна-Барр вируса и его жизненном цикле. Рассмотрены особенности патогенеза и иммунного ответа на внедрение вируса в клетку. Представлены предикторы тяжелых форм и различные варианты клиники Эпштейна-Барр вирусной инфекции. Ключевые слова Эпштейна-Барр вирус, хроническая Эпштейна-Барр вирусная инфекция, патогенез, иммунный ответ, клиника.

show abstract

Optimal treatment for chronic active Epstein–Barr virus disease

Cited by 51 publications

References 38 publications

Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation

Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation

Importance of the immune system in head and neck cancer

The clinical and immunological features of Epstein-Barr virus infection

Contact Info

Product

Resources

About